Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open‐label Continuation Arm of a Randomized Phase 3b Study

By  

PAIN PRACTICE, Vol. 15, Iss. 5, 2015-06 ,pp. : 471-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study*

By Hale Martin   Upmalis David   Okamoto Akiko   Lange Claudia   Rauschkolb Christine  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1095-1104

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain

By Daniels Stephen   Casson Ed   Stegmann Jens-Ulrich   Oh Charles   Okamoto Akiko   Rauschkolb Christine   Upmalis David  

Current Medical Research and Opinion, Vol. 25, Iss. 6, 2009-06 ,pp. : 1551-1561

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain*

By Daniels Stephen E.   Upmalis David   Okamoto Akiko   Lange Claudia   Häeussler Jüergen  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 765-776

Informa Healthcare

Access to resources Recommend Favorite

Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain

By  

EUROPEAN JOURNAL OF PAIN (ELECTRONIC), Vol. 20, Iss. 9, 2016-10 ,pp. : 1513-1518

John Wiley & Sons Inc

Access to resources Recommend Favorite